Overactive Bladder Treatment Market by Drug Type (Anticholinergics, Mirabegron, Botox, Neurostimulation, and Intravesical Instillation), Disease Type (Idiopathic Overactive Bladder and Neurogenic Overactive Bladder): Global Market Size Estimates and Forecast (2022-2030)

BMIRE00026029 | Pages: 100 | Pharmaceuticals | Sep 2022 | Type: Global | Status: Published

The market crossed the US$ 2.32 billion mark in 2022 and is expected to hit US$ 2.99 billion by 2030, recording a CAGR of 3.2% during the forecast period.

The overactive bladder treatment market has been significantly growing with increasing R&D investments.

The pharmaceuticals and biopharmaceutical companies are investing in innovative therapies for overactive bladder treatment. For instance, Urovant Sciences, a wholly owned subsidiary of Sumitovant Biopharma Ltd., announced new analyses from the Phase 3 EMPOWUR Extension Study of GEMTESA. According to the manufacturer, Gemtesa (vibegron, Urovant Sciences) helps to relax the detrusor bladder muscle, which enables the bladder to hold more urine, thereby reducing symptoms of overactive bladder. This is an additional demonstration of Urovant’s commitment to providing effective therapies for patients with urologic conditions. The adoption of treatment will increase with the launch of new novel treatments, which will subsequently increase the market growth.

Within the report, the market is segmented into drug type, disease type, and geography. By drug type, the market is segmented into anticholinergics, mirabegron, botox, neurostimulation, and intravesical instillation. Based on disease type, the market is bifurcated into idiopathic overactive bladder and neurogenic overactive bladder. Geographically, the market is sub-segmented into North America, Europe, Asia Pacific, South & Central America, and Middle East & Africa.

New technologies in the overactive bladder treatment will empower the market's growth.

Overactive bladder (OAB) is a clinical condition when the bladder muscle contracts involuntarily. Symptoms may include urinary urgency, urgency incontinence, frequent urination, and nocturia. Some other health conditions may also lead to an overactive bladder. Behavior modification, bladder training, and pelvic floor exercise are the first-line treatment for OAB. The second line of treatment is a trial of medications. Sacral neuromodulation for OAB is a next-generation implant that is more user-friendly and longer-lasting with fewer contraindications. For instance, on Sep 2022, Axonics, Inc., manufacturers of novel products for the treatment of bladder and bowel dysfunction, announced the first patient implants in Canada with the Axonics F15, the company’s newly developed, long-lived, fully recharge-free sacral neuromodulation (SNM) system.

The rising adoption of the neurostimulation segment is one of the major factors accelerating the market growth.

Urological applications of neuromodulation and neurostimulation are among the most evolving fields for the technologies. The neurostimulation segment will contribute to the market's growth during the forecast period. With the high prevalence of chronic kidney disease (CKD) and diabetes due to bladder muscle weakness in post-pregnancy and menopause, women are more vulnerable to the condition. According to the Urology Care Foundation, 30% of men and 40% of women live with OAB symptoms in the United States. This condition is more common in women over the age of 50.

Moreover, developments in the market are likely to propel the market’s growth. For instance, Valencia Technologies Corporation, a privately held company, announced on June 2022 that it had completed the world's first commercial implantation of eCoin in Sarasota, FL, after receiving premarket approval (PMA) from the U.S. Food and Drug Administration (FDA) in March 2022, making it the first and only FDA approved implantable tibial neurostimulator indicated for the treatment of urge urinary incontinence (UUI). Other segments such as anticholinergics, mirabegron, and botox are also encouraging the use of the technology.

Get more information on this report :

Recent strategic developments in the overactive bladder treatment market:

The overactive bladder treatment market has undergone several significant developments, and a few of these have been mentioned below:

  • In August 2021, the Israeli start-up Vensica Therapeutics Ltd. and Merz Therapeutics entered a strategic license and collaboration agreement to use Vensica’s innovative ultrasound-assisted delivery catheter to deliver botulinum neurotoxin A (Xeomin) to the bladder wall. With this agreement, Merz Therapeutics became the exclusive toxin supplier of any needleless application for urological indications, such as neurogenic bladder, overactive bladder, interstitial cystitis, and other urological symptoms.
  • In September 2022, Axonics Announces First Patient Implants in Canada with New Recharge-Free Sacral Neuromodulation System. The Axonics F15 received regulatory approval from Health Canada following U.S. FDA approval.
  • On 25 March 21, the U.S. Food and Drug Administration approved a new indication for Myrbetriq (mirabegron extended-release tablets) and Myrbetriq Granules (mirabegron for extended-release oral suspension) to treat neurogenic detrusor overactivity (NDO), bladder dysfunction related to neurological impairment.


Several players drive the overactive bladder treatment market by implementing strategic activities such as investments, new launches, mergers & acquisitions, and partnerships. Allergan plc, Astellas Pharma Inc., Laborie, Endo International Plc, Hisamitsu Pharmaceutical Co., Inc., Johnson & Johnson Services, Inc, Medtronic, Pfizer Inc., Sanofi, Teva Pharmaceutical Industries Ltd. are among the prominent players operating in the market.

The target audience for the report:

  • Government bodies, such as regulating authorities and policymakers
  • Venture capitalists, private equity firms, and start-up companies
  • End users
  • Research institutes, organizations

Scope of the report:

In this report, the market has been segmented based on:

  • Drug Type:
  • Anticholinergics
  • Mirabegron
  • Botox
  • Neurostimulation
  • Intravesical Instillation
  • Disease Type
    • Idiopathic Overactive Bladder
    • Neurogenic Overactive Bladder
  • Region
    • North America
    • Europe
    • Asia Pacific (APAC)
    • South & Central America
    • Middle East & Africa
  • Companies profiled
    • Allergan plc
    • Astellas Pharma Inc.
    • Laborie
    • Endo International Plc
    • Hisamitsu Pharmaceutical Co., Inc. 
    • Johnson & Johnson Services, Inc,
    • Medtronic
    • Pfizer Inc.,
    • Sanofi
    • Teva Pharmaceutical Industries Ltd.

Companies profiled
- Allergan plc
- Astellas Pharma Inc.
- Laborie
- Endo International Plc
- Hisamitsu Pharmaceutical Co., Inc.
- Johnson & Johnson Services, Inc,
- Medtronic
- Pfizer Inc.,
- Sanofi
- Teva Pharmaceutical Industries Ltd.

Report Code
Full Name
Country Name
Email Id
Phone Number
Job Title

Note : Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Purchase Options
Single User License
Site License
Enterprise License